TNP-2092 for injection

DRUG2 trials

Sponsors

TenNor Therapeutics Inc.

Conditions

Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Periprosthetic Joint Infection (PJI)Prosthetic Joints Infection (PJI)

Phase 1

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

CompletedNCT06394518

TenNor Therapeutics Inc.Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI)

Start: 2022-07-07End: 2023-02-24Updated: 2024-05-01

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

RecruitingNCT06889701

TenNor Therapeutics Inc.Periprosthetic Joint Infection (PJI)

Start: 2025-04-03End: 2026-08-01Target: 33Updated: 2026-03-05

Related Papers

P-1064. Safety, Tolerability, and Pharmacokinetics of Rifaquizone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study

Open Forum Infectious Diseases2025-01-291 citations